Amsterdam, The Netherlands, May 7, 2015; Kiadis Pharma B.V. (‘Kiadis Pharma’ or ‘the Company’), a clinical stage biopharmaceutical company developing innovative immunotherapy treatments, today announces the appointment of Dr. Vincent Brichard as an independent member of its Supervisory Board.
Dr. Brichard has more than 25 years’ experience in the oncology and immunology field, including almost 15 years at GlaxoSmithKline (GSK) where he was Senior Vice-President and had responsibility for the Immunotherapeutics Business Unit, which covered a broad, integrated approach to immunotherapy – from bench discovery through clinical development and operations to regulatory and commercial activities. In addition to this position, he served as a member of the Board of Directors at GSK Biologicals.
Dr. Brichard is a physician by training and holds a PhD in tumor immunology. He began his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. He further holds an MBA from the Harvard Business School.
Manfred Ruediger, CEO of Kiadis Pharma, commented: “We are very pleased to have attracted someone of Dr. Brichard’s caliber to the Board. His strong background and successful career in oncology and immunology will complement the Company’s already strong team and network. We look forward to benefiting from his counsel.”
Dr. Vincent Brichard commented: “With my background in oncology and immunology, my work has been focused since 1986 on the appealing project of educating our natural defenses – those that protect us from infectious diseases – to recognize and kill cancer cells. ATIR™ achieved some extremely compelling clinical data and the Phase II study interim analysis in December demonstrated the drug’s true potential as an adjunctive life-saving therapy for blood cancer patients. I am looking forward to joining the Board and working with the team to develop ATIR™ to its full potential.”
ATIR™ is a T-cell immunotherapy based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who do not have a standard of care matching stem cell donor available. A hematopoietic stem cell transplantation (HSCT) is the only potentially curative option for many patients but a matching donor is available for only half of the patients in need. ATIR™ thus has the potential to address this unmet need and to make an HSCT available for virtually all patients worldwide.
Those T-cells in a haploidentical donor graft which would cause Graft-versus-Host-Disease (GvHD) are selectively eliminated using proprietary technology to produce ATIR™. ATIR™ is administered as an adjunctive treatment after a T-cell depleted haploidentical HSCT, facilitating early immune reconstitution without causing life-threatening (acute) GvHD.
ATIR™ dovetails current approaches that render a patient eligible for a stem cell transplantation. Usually, only patients in remission are considered eligible for such a transplantation and so approaches that put refractory patients into remission, such as Chimeric Antigen Receptor (CAR) T-cell therapies, will increase the need for donors and potentially, therefore, the need for ATIR™.
In a Phase I/II study in which high-risk leukemia patients with very poor prognosis were treated with escalating doses of ATIR™ after a haploidentical HSCT, long-term safety, efficacy and proof of concept were confirmed in terms of absence of Grade III/IV (life-threatening) acute GvHD, reduced rates of infection, reduced Transplant Related Mortality and high Overall Survival. Positive follow-up results from this study demonstrate 78% survival after one year, 67% survival after five years and no Transplant Related Mortality in the nine patients who received a higher dose of ATIR™.
An international multi-center Phase II study including patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), to corroborate and extend the safety and efficacy results from the Phase I/II study, is now ongoing with interim data expected in the second half of 2014.
ATIR™ has been granted Orphan Drug Designation both in the EU and the USA. Together, both regions represent a combined primary market potential of more than EUR 1 billion per year.
About Kiadis Pharma
Kiadis Pharma B.V. is a private, clinical stage biopharmaceutical company focused on the development of innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders, an area of significant unmet medical need.
Kiadis Pharma’s lead product is ATIR™, a T-cell immunotherapy based medicinal product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors. Kiadis Pharma is collaborating with internationally renowned centers in Europe and North America for the successful development and manufacturing of ATIR™. Kiadis Pharma is working under a GMP manufacturing license and GMP certificate for its Quality Control laboratory.
Kiadis Pharma is supported by a strong group of leading international investors including LSP, DFJ Esprit, Alta Partners, Quest for Growth, NOM and MedSciences Capital. Kiadis Pharma is based in Amsterdam, The Netherlands.